AUD 0.0
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 | -3.53 Million AUD | 64.11% |
2023 | -9.86 Million AUD | 13.31% |
2022 | -11.37 Million AUD | -94.16% |
2021 | -5.85 Million AUD | -67.68% |
2020 | -3.49 Million AUD | -2.42% |
2019 | -3.41 Million AUD | -36.6% |
2018 | -2.49 Million AUD | -5.82% |
2017 | -2.35 Million AUD | -37.04% |
2016 | -1.72 Million AUD | 50.57% |
2015 | -3.48 Million AUD | 52.15% |
2014 | -7.28 Million AUD | -36.28% |
2013 | -5.34 Million AUD | 32.78% |
2012 | -7.94 Million AUD | 14.09% |
2011 | -9.25 Million AUD | 8.58% |
2010 | -10.12 Million AUD | 14.96% |
2009 | -11.9 Million AUD | -37.26% |
2008 | -8.66 Million AUD | 0.0% |
2007 | - AUD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -2.07 Million AUD | 0.0% |
2024 FY | -4.92 Million AUD | 50.1% |
2024 Q4 | -1.58 Million AUD | 0.0% |
2023 Q2 | -5.71 Million AUD | 0.0% |
2023 Q4 | -4.19 Million AUD | 0.0% |
2023 FY | -9.86 Million AUD | 13.31% |
2022 Q2 | -6.15 Million AUD | 0.0% |
2022 Q4 | -5.42 Million AUD | 0.0% |
2022 FY | -11.37 Million AUD | -94.16% |
2021 Q4 | -3.65 Million AUD | 0.0% |
2021 Q2 | -2.2 Million AUD | 0.0% |
2021 FY | -5.85 Million AUD | -67.68% |
2020 FY | -3.49 Million AUD | -2.42% |
2020 Q4 | -1.67 Million AUD | 0.0% |
2020 Q2 | -1.81 Million AUD | 0.0% |
2019 Q2 | -2.1 Million AUD | 0.0% |
2019 FY | -3.41 Million AUD | -36.6% |
2019 Q4 | -1.91 Million AUD | 0.0% |
2018 Q4 | -1.5 Million AUD | 0.0% |
2018 Q2 | -993.15 Thousand AUD | 0.0% |
2018 FY | -2.49 Million AUD | -5.82% |
2017 Q2 | -509.7 Thousand AUD | 0.0% |
2017 FY | -2.35 Million AUD | -37.04% |
2017 Q4 | -525.2 Thousand AUD | 0.0% |
2016 Q2 | -676.22 Thousand AUD | 0.0% |
2016 FY | -1.72 Million AUD | 50.57% |
2016 Q4 | -382.53 Thousand AUD | 0.0% |
2015 FY | -3.48 Million AUD | 52.15% |
2015 Q4 | -797.11 Thousand AUD | 0.0% |
2015 Q2 | -2.68 Million AUD | 0.0% |
2014 Q4 | -4.02 Million AUD | 0.0% |
2014 Q2 | -3.25 Million AUD | 0.0% |
2014 FY | -7.28 Million AUD | -36.28% |
2013 Q3 | -1.17 Million AUD | 6.85% |
2013 Q2 | -1.26 Million AUD | 18.24% |
2013 FY | -5.34 Million AUD | 32.78% |
2013 Q1 | -1.54 Million AUD | 0.0% |
2013 Q4 | -2.45 Million AUD | -109.36% |
2012 Q1 | -2.06 Million AUD | 0.0% |
2012 Q4 | -1.54 Million AUD | 0.0% |
2012 FY | -7.94 Million AUD | 14.09% |
2012 Q2 | -1.54 Million AUD | 25.21% |
2012 Q3 | -1.54 Million AUD | 0.0% |
2011 Q4 | -2.06 Million AUD | 0.0% |
2011 Q1 | -2.25 Million AUD | 0.0% |
2011 Q2 | -2.06 Million AUD | 8.76% |
2011 Q3 | -2.06 Million AUD | 0.0% |
2011 FY | -9.25 Million AUD | 8.58% |
2010 Q3 | -2.25 Million AUD | 0.0% |
2010 FY | -10.12 Million AUD | 14.96% |
2010 Q1 | -2.81 Million AUD | 0.0% |
2010 Q2 | -2.25 Million AUD | 19.64% |
2010 Q4 | -2.25 Million AUD | 0.0% |
2009 Q1 | -2.08 Million AUD | 0.0% |
2009 FY | -11.9 Million AUD | -37.26% |
2009 Q4 | -2.81 Million AUD | 0.0% |
2009 Q2 | -2.81 Million AUD | -34.5% |
2009 Q3 | -2.81 Million AUD | 0.0% |
2008 FY | -8.66 Million AUD | 0.0% |
2008 Q1 | - AUD | 0.0% |
2008 Q3 | -2.08 Million AUD | 0.0% |
2008 Q2 | -2.08 Million AUD | 0.0% |
2008 Q4 | -2.08 Million AUD | 0.0% |
2007 FY | - AUD | 0.0% |
2007 Q4 | - AUD | 0.0% |
2007 Q3 | - AUD | 0.0% |
2007 Q2 | - AUD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
EZZ Life Science Holdings Limited | 9.71 Million AUD | 136.424% |
Anatara Lifesciences Ltd | -1.45 Million AUD | -142.553% |
Zelira Therapeutics Limited | -5.93 Million AUD | 40.401% |
Biome Australia Limited | -1.91 Million AUD | -84.982% |
Orthocell Limited | -11.68 Million AUD | 69.702% |
Imugene Limited | -140.93 Million AUD | 97.489% |
Noxopharm Limited | -7.53 Million AUD | 53.031% |
PYC Therapeutics Limited | -38.85 Million AUD | 90.892% |
Chimeric Therapeutics Limited | -12.3 Million AUD | 71.249% |
Prescient Therapeutics Limited | -7.18 Million AUD | 50.752% |
Proteomics International Laboratories Limited | -7.23 Million AUD | 51.06% |
Cynata Therapeutics Limited | -8.8 Million AUD | 59.819% |
CSL Limited | 5.64 Billion AUD | 100.063% |
Arovella Therapeutics Limited | -7.19 Million AUD | 50.798% |
Bio-Gene Technology Limited | -3.06 Million AUD | -15.565% |
Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 107.201% |
Starpharma Holdings Limited | -15.15 Million AUD | 76.653% |
Nanollose Limited | -1.24 Million AUD | -183.172% |
Memphasys Limited | -2.7 Million AUD | -30.886% |
Invex Therapeutics Ltd | -2.13 Million AUD | -65.875% |
NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -72.091% |
Amplia Therapeutics Limited | -4.42 Million AUD | 20.019% |
Botanix Pharmaceuticals Limited | -14.69 Million AUD | 75.924% |
Island Pharmaceuticals Limited | -2.87 Million AUD | -23.153% |
Race Oncology Limited | -13.38 Million AUD | 73.55% |
Nyrada Inc. | -4.56 Million AUD | 22.393% |
Telix Pharmaceuticals Limited | - AUD | Infinity% |
Dimerix Limited | -25.05 Million AUD | 85.877% |
PharmAust Limited | -6.65 Million AUD | 46.849% |
Immutep Limited | -44.93 Million AUD | 92.124% |
Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 92.1% |
Alterity Therapeutics Limited | -19.6 Million AUD | 81.945% |
BTC Health Limited | 1.05 Million AUD | 435.373% |
Acrux Limited | -9.83 Million AUD | 64.011% |
Neuren Pharmaceuticals Limited | 225.96 Million AUD | 101.566% |
Biotron Limited | -5.15 Million AUD | 31.294% |
Tissue Repair Ltd | -4.87 Million AUD | 27.416% |
AdAlta Limited | -5.26 Million AUD | 32.736% |
Radiopharm Theranostics Limited | -47.2 Million AUD | 92.503% |
Hexima Limited | -1 Million AUD | -250.845% |
AnteoTech Limited | -11.72 Million AUD | 69.819% |
Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 94.565% |
Recce Pharmaceuticals Ltd | -22.05 Million AUD | 83.95% |
Avecho Biotechnology Limited | -4.58 Million AUD | 22.881% |
Actinogen Medical Limited | -12.83 Million AUD | 72.434% |
Immuron Limited | -5.8 Million AUD | 38.992% |
Argenica Therapeutics Limited | -5.67 Million AUD | 37.594% |